In a sterile, cold doctor's office, I was sitting opposite from a 37-year-old woman who had come in for her first ever Papanicolaou test, which was being offered as a part of our free cervical cancer screening program.I was holding her pathology report, on which the words "ATYPICAL SQUAMOUS CELLS (ASC-US)" were typed. I tried to explain to her what the Papanicolaou test was all about and what "ASC-US" could mean in terms of disease and, more importantly, what it most likely was not. I could see the anxiety, bewilderment, and confusion in her eyes. "So I have cancer?" she asked: surely atypical meant that it was not typical and that her diagnosis was bad. This was the first time that I had personally experienced this patient reaction to the word atypical first hand, but I am sure that our clinicians have this conversation routinely with their patients, witnessing similar anxiety in many of them.Furthermore, in this new era of pathology web portals, where pathology reports are becoming freely available to patients online, I can only imagine the apprehension of patients who pull their report and try to understand what we mean by atypical in their pathology report. After doing a internet search to find out what this mysterious disease might be and how it would affect them, they will find that the first hit is "Atypical Cells: Are They Cancer?," which, I am certain, is not very comforting.One of the major attributes of physicians should be the skill to empathize with, understand, and help patients. Therefore, as pathologists, we should strive to make our reports as clear and unequivocal as possible. This could ultimately prevent or minimize confusion and anxiety in both providers and patients and, we hope, prevent overtreatment of patients. In this issue of Cancer Cytopathology, VandenBussche et al 1 provide us with an introspective review of their institutional urothelial atypia rate over a 20-year span, which makes us ponder how we can do better. The stated primary goals of the Paris System for Reporting Urine Cytology (TPS) 2 were to refocus the emphasis of urine cytology on high-grade urothelial carcinoma (HGUC), to develop diagnostic categories with standardized definitions, and to increase the credibility of urine cytology. Not only did urinary cytology have low sensitivity for relatively indolent low-grade urothelial neoplasms, but it was also afflicted by an up to 50% rate of indeterminate diagnoses, 3 with a very low positive predictive value for malignancy. Faced with an almost coin-flip probability of having a diagnosis of atypical, urologists even called for abandoning urinary cytology altogether.
4Our daily experience shows that we cannot completely eliminate the diagnosis of atypia: it continues to be a useful category for filling the gap between what is recognizable as normal (or at least a version of normal) and what is recognizable as unequivocally abnormal. It still holds true that this diagnosis should be used sparingly. It cannot be overstressed that the potential overuse of atypia diagnoses can l...